Core Viewpoint - Weigao Blood Purification (603014.SH) plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. from Weigao Co., Weihe Shengxi, and Weihai Ruiming [1] Group 1: Transaction Details - The company will resume trading on November 3, 2025 [1] - The acquisition aims to integrate the target company's technological accumulation and product layout, expanding the product line into the pharmaceutical packaging sector [1] Group 2: Strategic Benefits - Post-transaction, the company can leverage its hollow fiber filtration technology alongside the target company's extensive customer resources in biopharmaceuticals [1] - This collaboration is expected to enhance both parties' product technology reserves and sales channels, focusing on the biopharmaceutical filter business and expanding into the upstream biopharmaceutical market [1]
威高血净(603014.SH)拟购买山东威高普瑞医药包装有限公司100%股权 股票复牌